MedPath

Kwality Pharma Gains Approval for Leuprorelin Acetate Injectable Suspension in Greece

• Kwality Pharmaceuticals Limited (KPL) has secured approval in Greece for its Leuprorelin Acetate 11.25 mg injectable suspension, marking its entry into the European market. • The company plans to supply initial validation batches by December, with regular supplies commencing from January 2025 after thorough quality control analysis. • This strategic CDMO arrangement is expected to generate approximately USD 3 million in annual sales, with distribution starting in the fourth quarter of this fiscal year.

Kwality Pharmaceuticals Limited (KPL) has announced that it has received approval for its Leuprorelin Acetate 11.25 mg vial powder and solvent for injectable suspension in Greece. This approval signifies KPL's entry into the European market.
The company is set to supply the first three validation batches in December. Following complete Quality Control Analysis, regular supplies are scheduled to commence from January 2025 onwards. This strategic CDMO arrangement is projected to generate around USD 3 million in yearly sales, with distribution set to begin in the 4th Quarter of this fiscal year. Furthermore, there are plans to add remaining strengths of the same in the product portfolio with the same buyer as well.
This approval marks a pivotal step in the company's strategy to introduce its products in highly regulated markets.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Pharming's Leniolisib Shows Positive Phase 3 Data in Young Children with APDS

Pharming's leniolisib demonstrated positive topline results in a Phase 3 trial for children aged 4-11 with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS).
The study showed improvements in lymphoproliferation and immunophenotype correction, consistent with results from trials in older patients.

EU Approves AbbVie's Elahere for Platinum-Resistant Ovarian Cancer

The European Commission has granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) for platinum-resistant ovarian cancer treatment.
Elahere is the first folate receptor alpha (FRα)-directed antibody-drug conjugate approved in the EU, targeting FRα-positive ovarian cancer in adults.

European Commission Approves AbbVie's Elahere for Platinum-Resistant Ovarian Cancer

The European Commission has approved AbbVie's Elahere (mirvetuximab soravtansine) for treating folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer.
Elahere is the first and only FRα-directed antibody-drug conjugate approved in the EU, Iceland, Liechtenstein, Norway, and Northern Ireland.

Aflibercept Biosimilars Gain Momentum in Europe with Multiple Approvals and Positive Opinions

The European Medicines Agency's CHMP recommended Amgen's Pavblu and Skojoy, aflibercept biosimilars, for approval in January 2025, expanding treatment options for retinal diseases.
Sandoz's Afqlir (aflibercept) received marketing authorization from the European Commission, offering an affordable alternative for conditions like neovascular AMD, expected to launch in Q4 2025.

Eisai and Biogen Seek Approval for Leqembi Autoinjector, Aiming for 2025 Launch

Eisai and Biogen have completed their application for a subcutaneous autoinjector formulation of Leqembi, targeting a less burdensome administration for Alzheimer's patients.
The autoinjector, designed for once-weekly use after an intravenous induction, could differentiate Leqembi from competitors like Eli Lilly's Kisunla and boost its uptake.

Eisai and Biogen Pursue Subcutaneous Leqembi Approval for Alzheimer's

Eisai and Biogen have completed their application for a subcutaneous formulation of Leqembi, aiming for approval in 2025.
The subcutaneous version offers a less burdensome, once-weekly autoinjector, potentially enhancing patient convenience and drug uptake.

FDA Reviewing Ready-to-Use 3-Month Leuprolide Depot for Advanced Prostate Cancer

Foresee Pharmaceuticals' new drug application for a ready-to-use 3-month depot formulation of leuprolide mesylate (Camcevi) is under FDA review for advanced prostate cancer treatment.
Phase 3 trial data showed 97.9% of patients achieved target testosterone suppression by day 28, sustaining it through day 168, supporting the NDA submission.

European Commission Approves Pembrolizumab Regimens for Endometrial and Cervical Cancers

The European Commission approved pembrolizumab plus carboplatin/paclitaxel as first-line treatment for advanced or recurrent endometrial carcinoma in adults eligible for systemic therapy.
Pembrolizumab combined with chemoradiotherapy (CRT) also received approval for previously untreated stage III to IVA locally advanced cervical cancer in adult patients.

Leo Pharma's Delgocitinib Filing Accepted in the US, Expanding JAK Inhibitor Market

Leo Pharma's delgocitinib, a JAK inhibitor, has been accepted for filing in the US, marking a significant step towards entering the American market.
The drug has already received approval in Europe, positioning it as a key growth driver for the Danish dermatology company.

Mereo BioPharma Advances Rare Disease Pipeline with Setrusumab and Alvelestat

Mereo BioPharma's partner, Ultragenyx, anticipates completing enrollment for the Phase 3 Orbit study of setrusumab in Osteogenesis Imperfecta (OI) by the end of Q1 2024.
A global Phase 3 study design for alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) has been aligned upon following interactions with the FDA.

Reference News

[1]
Kwality Pharma received approval for Leuprorelin Acetate for injectable suspension from Greece
indianpharmapost.com · Nov 7, 2024

Kwality Pharmaceuticals Limited (KPL) has received approval for Leuprorelin Acetate 11.25 mg vial powder and solvent for...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy